Management

D. Elliot Parks, Ph.D.
President and CEO

Dr. Elliot Parks brings over twenty-five years in biomedical research, product development, executive management, and international venture capital experience to the company. During that time he has had extensive experience in successfully and repeatedly translating important basic research science into commercial products. He was the founding CEO of Myelos Neurosciences a venture-backed, clinical stage biologics company sold to Savient, a NASDAQ listed firm. Prior to Myelos, Dr. Parks was the Director of the Johnson & Johnson Biotechnology Center for ten years, where he was responsible for guiding several biomedical products through clinical trials and regulatory approval. Following receipt of his Ph.D. in Microbiology and Immunology at the University of Washington in Seattle, Dr. Parks assumed research and leadership positions at the Scripps Research Institute during his twelve year tenure there. He also served under the Surgeon General of the Army at Letterman Army Institute of Research in the Presidio in San Francisco.

Richard L. Sherman, J.D.
Vice President, Business Development and General Counsel

Mr. Sherman has twenty-five years of experience as a licensing executive, attorney, consultant, and venture capitalist in the biotechnology and pharmaceutical industries. As a licensing executive and Deputy General Counsel in a thirteen year career at SmithKline-Beckman Corporation, Mr. Sherman participated as counsel and negotiator in hundreds of international and domestic transactions; including hostile and friendly acquisitions, divestitures, joint ventures, limited partnerships, research and development collaborations, venture capital investments, joint marketing relationships, distribution arrangements, and licensing transactions. Mr. Sherman also founded QED Technologies, Inc., a consulting firm that provides science-based companies with experienced advice and counsel in developing and implementing strategies to maximize their business and technology assets. QED's clients include pharmaceutical, biotechnological, chemical, diagnostic and medical device firms; universities and independent research centers; investment groups and funds. QED was purchased by The Omnicom Group, Inc., a NYSE listed firm.